Q4 2018 Earnings Forecast for PRA Health Sciences Inc Issued By KeyCorp (PRAH)

PRA Health Sciences Inc (NASDAQ:PRAH) – Stock analysts at KeyCorp raised their Q4 2018 EPS estimates for shares of PRA Health Sciences in a research report issued to clients and investors on Thursday, November 1st. KeyCorp analyst D. Hooker now expects that the medical research company will post earnings per share of $1.20 for the quarter, up from their previous forecast of $1.14. KeyCorp has a “Buy” rating and a $115.00 price objective on the stock.

PRA Health Sciences (NASDAQ:PRAH) last announced its quarterly earnings data on Wednesday, October 31st. The medical research company reported $1.13 EPS for the quarter, topping analysts’ consensus estimates of $1.07 by $0.06. PRA Health Sciences had a return on equity of 25.75% and a net margin of 2.37%. The business had revenue of $717.60 million during the quarter, compared to analysts’ expectations of $729.63 million. During the same period in the previous year, the firm earned $0.88 earnings per share. The firm’s quarterly revenue was up 23.3% compared to the same quarter last year.

A number of other research analysts have also recently issued reports on the company. Credit Suisse Group boosted their target price on PRA Health Sciences from $104.00 to $107.00 and gave the company an “outperform” rating in a research note on Thursday, August 2nd. Mizuho set a $100.00 target price on PRA Health Sciences and gave the company a “hold” rating in a research note on Monday, August 6th. Barclays boosted their target price on PRA Health Sciences from $100.00 to $115.00 and gave the company an “overweight” rating in a research note on Thursday, August 2nd. BidaskClub raised PRA Health Sciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 25th. Finally, Robert W. Baird boosted their target price on PRA Health Sciences from $112.00 to $116.00 and gave the company an “outperform” rating in a research note on Tuesday, September 11th. Two equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $111.50.

Shares of PRA Health Sciences stock opened at $104.25 on Monday. The company has a quick ratio of 0.93, a current ratio of 0.89 and a debt-to-equity ratio of 1.22. PRA Health Sciences has a 12 month low of $76.39 and a 12 month high of $112.88. The firm has a market cap of $6.47 billion, a P/E ratio of 32.58, a P/E/G ratio of 1.47 and a beta of 0.73.

In other news, major shareholder Pra Investors L.P. Kkr sold 6,500,000 shares of the company’s stock in a transaction dated Thursday, August 9th. The stock was sold at an average price of $101.01, for a total transaction of $656,565,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 0.85% of the stock is owned by corporate insiders.

Several hedge funds have recently bought and sold shares of the company. Carnegie Capital Asset Management LLC boosted its position in shares of PRA Health Sciences by 0.9% during the second quarter. Carnegie Capital Asset Management LLC now owns 59,966 shares of the medical research company’s stock worth $6,083,000 after buying an additional 556 shares during the period. Strs Ohio boosted its position in shares of PRA Health Sciences by 14.2% during the third quarter. Strs Ohio now owns 4,582 shares of the medical research company’s stock worth $504,000 after buying an additional 569 shares during the period. Bank of Montreal Can boosted its position in shares of PRA Health Sciences by 12.8% during the third quarter. Bank of Montreal Can now owns 6,491 shares of the medical research company’s stock worth $715,000 after buying an additional 738 shares during the period. Securian Asset Management Inc boosted its position in shares of PRA Health Sciences by 12.4% during the third quarter. Securian Asset Management Inc now owns 7,071 shares of the medical research company’s stock worth $779,000 after buying an additional 780 shares during the period. Finally, State of Alaska Department of Revenue boosted its position in shares of PRA Health Sciences by 13.9% during the third quarter. State of Alaska Department of Revenue now owns 6,984 shares of the medical research company’s stock worth $769,000 after buying an additional 854 shares during the period. 98.82% of the stock is owned by institutional investors.

About PRA Health Sciences

PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

Featured Story: Bull Market

Earnings History and Estimates for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply